Earnings call briefThird-quarter 2026
Novo Nordisk says Wegovy pill to reach more than 20 markets by first half 2027
The company said the pill has launched in seven markets outside the U.S. so far, with further launches planned during the fourth quarter.
GetSignal Novo Nordisk A/S NVO
Novo Nordisk said on its third-quarter call that it now expects Wegovy pill to be available in more than 20 markets by first half of 2027, up from a target of 20 markets by end of next year set at its Capital Markets Day.
The company said the pill's market share in the U.K. is around 90% in oral obesity, and that it is also rolling out Wegovy 7.2 mg in more markets.
Quotes from the call
“By first half of 2027, we now expect Wegovy pill to be available in more than 20 markets.”
Key facts from the call
- Wegovy pill outlook
- More than 20 markets by first half of 2027
- Wegovy pill launches to date
- Seven markets outside the U.S.
Source: Novo Nordisk's third-quarter 2026 earnings call, November 4, 2026.
Written by GetSignal with AI from the company's earnings call.
Not investment advice.
More earnings call briefs
- Constellation Energy expects nuclear uprate costs of about $4.3 billion
CEG Constellation Energy Q3 2026 call
- Howard Hughes Holdings says its insurance ambition is a return on equity in excess of 20%
HHH Howard Hughes Holdings Q3 2026 call
- Brookfield Asset Management now sees 2026 earnings modestly below early view
BAM Brookfield Asset Management Q3 2026 call
- Enbridge says it expects 2026 results at the midpoint of its guidance range
ENB Enbridge Q3 2026 call
- TeraWulf sees about half of contracted IT capacity earning revenue by end of Q1
WULF TeraWulf Q3 2026 call
